JAK Inhibitors for Severe Skin Reactions from Cancer Immunotherapy
Part of Cancer, Skin clinical trials.
This trial tests whether a JAK inhibitor (a type of drug) can help patients with solid cancers who developed severe skin rashes from immunotherapy drugs and didn't get better with steroids. The goal is to find a new treatment option for this painful side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with a solid cancer (not blood cancer)
- You have received FDA-approved immunotherapy drugs (like Opdivo, Keytruda, or Yervoy) that target the immune system
- You developed a severe skin rash (grade 3 or 4) from your immunotherapy
- Your skin rash didn't improve with steroid creams or other immune-suppressing treatments
- Your blood counts and liver/kidney function are within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Hear when a new Immune Checkpoint Inhibitor-Induced Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.